OSIR News Alert Osiris Therapeutics (OSIR) 13.13 12/17/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Osiris Therapeutics (OSIR) 13.13 $OSIR

Commit To Buy Osiris Therapeutics At $11, Earn 9.9% Annualized Using Options
at The Street - Mon Dec 15, 11:18AM CST
Investors considering a purchase of Osiris Therapeutics Inc shares, but cautious about paying the going market price of $12.83/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
OSIR: 13.13 (+0.16)

Is Osiris Therapeutics (OSIR) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 7:34AM CST
Osiris Therapeutics is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
OSIR: 13.13 (+0.16)

New medical chief at Osiris
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 8:13AM CST

OSIR: 13.13 (+0.16)

Osiris Therapeutics Announces Expansion of the Leadership Team
Business Wire - Wed Dec 03, 7:02AM CST
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, is pleased to announce the expansion of the management team with the appointment of Adrian Mollo as General Counsel and Dr. Jon Hopper as Chief Medical Officer, both reporting to Lode Debrabandere, Ph.D., President and Chief Executive Officer. Gregory Law also recently joined the Osiris management team as Vice President of Finance and Principal Accounting Officer, reporting to Philip Jacoby, Chief Financial Officer.
OSIR: 13.13 (+0.16)

Osiris Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
Business Wire - Mon Dec 01, 7:01AM CST
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that Lode Debrabandere, Ph.D., President and Chief Executive Officer, is scheduled to present at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 3:00 p.m. ET in New York City.
OSIR: 13.13 (+0.16)

Osiris Therapeutics Earnings Hindsight: Down 2.8% in Last 17 Days (OSIR)
Comtex SmarTrend(R) - Mon Nov 24, 9:24AM CST
Two weeks ago on November 7th, 2014 Osiris Therapeutics (NASDAQ:OSIR) reported earnings and analysts, on average, expected a loss of $0.02 on sales of $14.8 million. Osiris Therapeutics actually reported earnings of $0.02 per share on sales of $17.2 million, beating EPS estimates by $0.04 and beating revenue estimates by $2.4 million. Since the company's report, shares of Osiris Therapeutics have fallen from $13.50 to $13.12, representing a loss of 2.8% in the past 17 days.
OSIR: 13.13 (+0.16)

Earnings Look Back: Osiris Therapeutics Is Down 3.3% Since Reporting Quarterly Results 1 Week Ago (OSIR)
Comtex SmarTrend(R) - Mon Nov 17, 3:25PM CST
When Osiris Therapeutics (NASDAQ:OSIR) reported earnings a week ago on November 7th, 2014, analysts, on average, expected the company to report a loss of $0.02 on sales of $14.8 million. Osiris Therapeutics actually reported earnings of $0.02 per share on sales of $17.2 million, beating EPS estimates by $0.04 and beating revenue estimates by $2.4 million. Shares of Osiris Therapeutics have slipped from $13.50 to $13.05, representing a loss of 3.3%, since the company reported earnings 10 days ago.
OSIR: 13.13 (+0.16)

Osiris Therapeutics to Present at the Canaccord Genuity Medical Technology and Diagnostics Forum
Business Wire - Mon Nov 17, 7:02AM CST
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that Lode Debrabandere, Ph.D., President and Chief Executive Officer, is scheduled to present at the Canaccord Genuity Medical Technology and Diagnostics Forum on Thursday, November 20, 2014 at 9:00 a.m. ET in New York City.
OSIR: 13.13 (+0.16)

Osiris Therapeutics Beats on Q3 Earnings & Revenues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Nov 11, 8:00AM CST
Osiris Therapeutics (OSIR) performed well above expectations with revenues increasing significantly.
CYTK: 4.57 (+0.09), BIIB: 325.13 (-10.67), OSIR: 13.13 (+0.16), AMAG: 40.30 (+1.29)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 4:35PM CST

AGTC: 19.91 (+0.06), BXE: 3.23 (+0.24), ROKA: 3.98 (unch), ALNY: 92.08 (-1.87), NCT: 4.71 (-0.07), SSRI: 4.26 (-0.23), ABCB: 25.76 (+0.12), OSIR: 13.13 (+0.16), XCO: 2.16 (+0.05), JDST: 25.88 (+1.96)

Osiris Therapeutics' (OSIR) CEO Lode Debrabandere on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 11:00AM CST

OSIR: 13.13 (+0.16)

Osiris ups revenues 149% in Q3
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:19AM CST

OSIR: 13.13 (+0.16)

Osiris Therapeutics (OSIR) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Fri Nov 07, 7:55AM CST

OSIR: 13.13 (+0.16)

Osiris Therapeutics beats by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 7:10AM CST

OSIR: 13.13 (+0.16)

Osiris posts 3Q profit
Automated Insights - Fri Nov 07, 7:09AM CST
COLUMBIA, Md. (AP) _ Osiris Therapeutics Inc. (OSIR) on Friday reported net income of $645,000 in its third quarter.
OSIR: 13.13 (+0.16)

Osiris Therapeutics Announces Third Quarter 2014 Financial Results: Revenue up 29% and Company Turned Profitable
Business Wire - Fri Nov 07, 7:00AM CST
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedic and sports medicine, announced today its financial results for the third quarter of 2014.
OSIR: 13.13 (+0.16)

Reckitt Benckiser Pharmaceuticals Inc. Announces Appointment of Chief Financial Officer
PR Newswire - Tue Nov 04, 7:00AM CST
Reckitt Benckiser Pharmaceuticals Inc., a global specialty pharmaceutical company committed to pioneering innovative and accessible therapies for the chronic diseases of addiction and related mental health disorders, today announced the appointment of Cary J. Claiborne as Chief Financial Officer. Cary will lead the company's global financial and information technology operations, reporting to Chief Executive Officer Shaun Thaxter effective November 10, 2014.
SCMP: 12.89 (+0.23), OSIR: 13.13 (+0.16)

Japan Gives A Hug To The Cell Therapy Industry: R. Lee Buckler
Life Sciences Report - Seeking Alpha - Fri Oct 24, 7:21AM CDT
Last year, Japan rolled out the red carpet for cell therapy developers with new legislation designed to expedite development of regenerative medicine solutions for all manner of disease. In this interview with The Life Sciences Report , former...
PSTI: 2.47 (-0.07), UTHR: 126.04 (-2.81), OSIR: 13.13 (+0.16), ATHX: 1.23 (-0.04)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 176

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 143

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 142

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 214

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 196

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 136

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 76

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 126

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 198

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading

Top 5 Most Recently Viewed Articles

Breaker’s TruSend™: A Game Changer in Email Marketing

Updated Category News Views 142

Breaker’s TruSend™: A Game Changer in Email Marketing In the fast-evolving world of marketing, email continues to hold its ground as a vital communication tool. Breaker has recognized the challenges marketers face with fragmented tech stacks and has introduced TruSend™, a robust email distribution platform. This innovation streamlines the email marketing process,...

Continue Reading
DigiKey and Qorvo Collaborate to Enhance Global Distribution

Updated Category News Views 151

DigiKey and Qorvo Forge Strategic Distribution Partnership DigiKey, a prominent global distributor known for its vast selection of technical components and automation products, has entered into a vital distribution agreement with Qorvo®, a leader in connectivity and power solutions. This collaboration aims to boost the availability and delivery speed of Qorvo's...

Continue Reading
Lloyds Bank's Financial Insights for 2025: A Comprehensive Review

Updated Category News Views 345

Overview of Lloyds Bank plc's 2025 Half-Year Results Lloyds Bank plc, a prominent player in the financial services sector, has released its half-year results for 2025, demonstrating resilience and strategic agility. As a member of the Lloyds Banking Group, it continues to show its commitment to delivering value to its stakeholders and customers. Key Financial Highlights...

Continue Reading
Advansor's Latest CO2 Enclosure Solutions Revolutionize Climate Control

Updated Category News Views 97

Advansor Introduces a New Range of CO2 Enclosures Advansor, a leading name in climate solutions, has recently unveiled an innovative line of CO2 enclosures tailored for supermarkets, cold storage facilities, and industrial applications. These enclosures are designed to simplify on-site installations and offer flexible options for outdoor placement. This groundbreaking...

Continue Reading
LG Innotek's Revolutionary Automotive AP Module Enhances Mobility

Updated Category News Views 220

LG Innotek's Innovative Entry into Automotive Semiconductor Market LG Innotek has taken a significant step into the automotive semiconductor component market with the launch of its Automotive Application Processor Module (AP Module). This move comes in response to a growing demand for sophisticated automotive technologies, particularly in the realm of Advanced Driver...

Continue Reading